Issue 8, 2022, Issue in Progress

Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

Abstract

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an MRI contrast agent for detecting the amyloid-β (Aβ) fibrillation process. Gd-DO3A-Comp.B inhibited Aβ aggregation significantly and detected the fibril growth at 20 μM of Aβ with 10 μM of probe concentration by T1-weighted MR imaging.

Graphical abstract: Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

Supplementary files

Article information

Article type
Paper
Submitted
29 Jan 2022
Accepted
01 Feb 2022
First published
09 Feb 2022
This article is Open Access
Creative Commons BY license

RSC Adv., 2022,12, 5027-5030

Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

R. Y. Utomo, S. Okada, A. Sumiyoshi, I. Aoki and H. Nakamura, RSC Adv., 2022, 12, 5027 DOI: 10.1039/D2RA00614F

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements